{
    "2020-12-06": [
        [
            {
                "time": "2023-12-09",
                "original_text": "浙商早知道 | 12月9日",
                "features": {
                    "keywords": [
                        "BCL-2抑制剂",
                        "获批",
                        "维奈克拉",
                        "艾伯维",
                        "重磅产品"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-12-09",
                "original_text": "热门融资标的股票分析",
                "features": {
                    "keywords": [
                        "融资",
                        "标的股票",
                        "分析"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "投资"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-12-09",
                "original_text": "国内首个BCL-2抑制剂获批 维奈克拉有望成艾伯维重磅产品",
                "features": {
                    "keywords": [
                        "BCL-2抑制剂",
                        "获批",
                        "维奈克拉",
                        "艾伯维",
                        "重磅产品"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}